[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349637-105":59,"doc-detail-349637-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","economic-burden-of-cancer-care-in-lebanons-privately-insured-population-a-seven-year-retrospective-cohort-analysis-2018-2024","Economic burden of cancer care in Lebanon’s privately insured population - a seven-year retrospective cohort analysis (2018-2024)","","Cancer care creates an expanding economic burden on health systems globally, yet longitudinal, population-level evidence on cancer costs within private insurance remains limited in low- and middle-income settings. This study analyzes Lebanese third-party administrator claims from 2018–2024 to quantify demographics, cancer type, utilization, cost trends, per-member-per-year (PMPY) spending, and a high-cost cohort (≥USD 100,000 over 365 days).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/economic-burden-of-cancer-care-in-lebanons-privately-insured-population-a-seven-year-retrospective-cohort-analysis-2018-2024/349637/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/economic-burden-of-cancer-care-in-lebanons-privately-insured-population-a-seven-year-retrospective-cohort-analysis-2018-2024/349637.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and timeframe were used to estimate the economic burden of cancer care?","Question",{"text":112,"@type":113},"A retrospective cohort analysis used event-level insurance claims from a leading Lebanese third-party administrator covering 2018–2024.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was cancer identified in the claims data?",{"text":117,"@type":113},"Claims with ICD-10 cancer diagnosis codes in C or D series (excluding benign neoplasms D10–D36) were processed through a standardized event-to-patient pipeline.",{"name":119,"@type":110,"acceptedAnswer":120},"What proportion of spending was accounted for by the high-cost cohort?",{"text":121,"@type":113},"A high-cost cohort of 285 patients (1.7%) accounted for USD 55.1 million, representing 23.0% of total spend.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349637,1790626516,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 25 August 2026 DOI 10.3389/fonc.2026.1924237  \nOPEN ACCESS  \nEDITED BY  \nShirley Morrison Bluethmann,  \nWake Forest University, United States  \nREVIEWED BY  \nJoseph Gergi Kattan,  \nHˆotel-Dieu de France, Lebanon Anes Jogunˇcic´,  \nPublic Health Institute of Canton Sarajevo, Bosnia and Herzegovina  \n*CORRESPONDENCE  \nShadi Saleh  \n [ss117@aub.edu.lb](ss117@aub.edu.lb)  \nRECEIVED 30 June 2026  \nREVISED 29 July 2026  \nACCEPTED 06 August 2026  \nPUBLISHED 25 August 2026  \nCITATION  \nSaleh S, Makhoul P, Chamandi R and Abdul-Sater Z (2026) Economic burden of cancer care in Lebanon ’s privately insured population: a seven-year retrospective cohort analysis (2018–2024) .  \nFront. Oncol. 16:1924237 .  \ndoi: 10.3389/fonc.2026.1924237  \nCOPYRIGHT  \n© 2026 Saleh, Makhoul, Chamandi and Abdul-Sater. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEconomic burden of cancer care in Lebanon’s privately insured population: a seven-year retrospective cohort analysis (2018–2024)  \nShadi Saleh 1,2*, Paul Makhoul 3, Rawad Chamandi 3 and Zahi Abdul-Sater 2,4  \n1 Department of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, 2Global Health Institute, American University of Beirut, Beirut, Lebanon,  \n3 Market Access, AstraZeneca, Beirut, Lebanon, 4College of Public Health, Phoenicia University, Mazraat El Daoudiyeh, Lebanon  \nBackground: Cancer imposes a growing economic burden on health systems globally, yet longitudinal, population-level data on cancer care costs within private insurance remain scarce in low- and middle-income countries. Lebanon ’ s private insurance sector, administered through third-party administrators (TPAs), covers a substantial share of the economically active population, yet no published study has characterized its cancer-related economic burden, including during the country ’ s economic contraction since 2019 .  \nMethods: A retrospective cohort analysis used event-level insurance claims from a leading Lebanese TPA for 2018–2024 . Claims carrying an ICD-10 cancer diagnosis code (C or D series, excluding benign neoplasms D10–D36) were processed through a standardized pipeline from event to patient level. Analyses covered demographics, cancer type distribution, treatment and service utilization, cost trends, per-member-per-year (PMPY) expenditure, and a high-cost cohort (HCC) deﬁned as USD 100,000 or more in cumulative costs within any rolling 365-day window.  \nResults: The cohort comprised 16,617 unique cancer patients generating 157,550 claims and USD 239 . 9 million in total expenditure over seven years. Females accounted for 53.7% of patients; breast cancer was the most prevalent diagnosis (19 .7%), in the predominant 40–64-year age group (50 . 2%) . Surgery was the most common treatment modality (29.3%), followed by cancer medicines (24.2%) and radiotherapy (14.9%), yet cancer medicines were the largest cost category (37.8% of spend) . Annual expenditure rose from USD 35 .7 million (2018) to USD 48 .9 million (2024), with a transient compression in 2022 . A high-cost cohort of 285 patients (1.7%) accounted for USD 55.1 million (23.0% of spend), led by lung cancer (19 .7%) . Cancer patient rates rose 24 . 5%(1,015 to 1,263 per 100,000), and permember cost rose steeply with age, reaching USD 606 PMPY among patients aged 65+ in 2024 versus USD 15–169 in younger groups; overall PMPY reached USD 111 . 50, recovering from the 2022 trough.  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nConclusions: This study provides the ﬁrst ","cbCaic8VCYWix3wo","https://ap.wps.com/l/cbCaic8VCYWix3wo","pdf",3589238,13,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What data and timeframe were used to estimate the economic burden of cancer care?\",\"answer\":\"A retrospective cohort analysis used event-level insurance claims from a leading Lebanese third-party administrator covering 2018–2024.\"},{\"question\":\"How was cancer identified in the claims data?\",\"answer\":\"Claims with ICD-10 cancer diagnosis codes in C or D series (excluding benign neoplasms D10–D36) were processed through a standardized event-to-patient pipeline.\"},{\"question\":\"What proportion of spending was accounted for by the high-cost cohort?\",\"answer\":\"A high-cost cohort of 285 patients (1.7%) accounted for USD 55.1 million, representing 23.0% of total spend.\"}]","Economic burden of cancer care in Lebanon’s privately insured population - a seven-year retrospective cohort analysis (2018-2024) | PDF",1790084622,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1639eeb83b67b685d00d59db4e5ff78.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b60acdd7d6bf35c77372aca0dbf6f2f4.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44c6542cae547d297b42f7e9f1b70697.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a5e58a4a85a71ae952ed4981f0928db.webp",980,1385]